(Total Views: 174)
Posted On: 10/27/2018 9:36:51 AM
Post# of 86157
MilliporeSigma, the life science business of Merck KGaA, Darmstadt, Germany, has 19,000 employees and 72 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. MilliporeSigma comprises the legacy EMD Millipore organization and Sigma-Aldrich Corporation following its acquisition by Merck KGaA, Darmstadt, Germany in 2015. Through collaboration with the global, scientific community, MilliporeSigma serves as a strategic partner to customers with the goal of accelerating access to healthcare worldwide. MilliporeSigma has operations in 67 countries and combined 2014 revenues of €4.6 billion.
MilliporeSigma home offices located in Sheboygan Falls, Wisconsin.
MilliporeSigma is the Merck division that in my opinion would be spun off so Merck can enter the cannabis industry without hurting its revenue from its major drug lines. MilliporeSigma already developed and markets a “blank” transdermal patch and it is medically approved for clinical trials and is said to be the best on the market. So, what does MilliporeSigma need? MilliporeSigma needs the pharmacological grade cannabis medicine that makes the “blank” patch a cannabis transdermal patch. Univec and AGRiMED formed a partnership specifically to develop the pharmacy grade cannabis medicine for such a patch, and so here we are today.
After the November elections, the White House is said to be coming out with new recommendations on cannabis in the United States. If true, and if some form of legalization is approved, that could be the beginning of a sea change in the way cannabis is viewed in this country. And, it could be the beginning steps for an industry that could mint millionaires by the hundreds or perhaps even the thousands (In fact, some of you might be one of those millionaires). Our time is near folks, and that time could very well begin in November.
Kgem
MilliporeSigma home offices located in Sheboygan Falls, Wisconsin.
MilliporeSigma is the Merck division that in my opinion would be spun off so Merck can enter the cannabis industry without hurting its revenue from its major drug lines. MilliporeSigma already developed and markets a “blank” transdermal patch and it is medically approved for clinical trials and is said to be the best on the market. So, what does MilliporeSigma need? MilliporeSigma needs the pharmacological grade cannabis medicine that makes the “blank” patch a cannabis transdermal patch. Univec and AGRiMED formed a partnership specifically to develop the pharmacy grade cannabis medicine for such a patch, and so here we are today.
After the November elections, the White House is said to be coming out with new recommendations on cannabis in the United States. If true, and if some form of legalization is approved, that could be the beginning of a sea change in the way cannabis is viewed in this country. And, it could be the beginning steps for an industry that could mint millionaires by the hundreds or perhaps even the thousands (In fact, some of you might be one of those millionaires). Our time is near folks, and that time could very well begin in November.
Kgem
(2)
(0)Scroll down for more posts ▼
